Related Experiment Video
Updated: Jan 23, 2026
07:20
Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium
Published on: April 9, 2019
9.7K
Summary
Adding enzalutamide to standard treatment significantly improves survival for men with metastatic hormone-sensitive prostate cancer. This global ENZAMET trial shows superior outcomes compared to older nonsteroidal antiandrogen drugs.
Area of Science:
- Oncology
- Clinical Trials
- Prostate Cancer Research
Background:
- Metastatic hormone-sensitive prostate cancer (mHSPC) requires effective treatment strategies to prolong patient survival.
- Traditional treatment involves nonsteroidal antiandrogen drugs, but their efficacy in improving overall survival is being re-evaluated.
- The ENZAMET trial investigated novel therapeutic approaches for mHSPC patients.
Discussion:
- The ENZAMET trial is a global, phase III study comparing enzalutamide plus standard treatment versus placebo plus standard treatment in men with mHSPC.
- Results indicate a significant benefit in overall survival for patients receiving enzalutamide.
- The study provides robust evidence supporting the use of enzalutamide in this patient population.
Key Insights:
- Enzalutamide addition to standard therapy demonstrates superior survival benefits in metastatic hormone-sensitive prostate cancer.
- The study confirms enzalutamide's efficacy over older nonsteroidal antiandrogen drugs in prolonging life.
- Phase III ENZAMET trial results offer a new standard of care for mHSPC.
Outlook:
- Further research may explore optimal sequencing and combination therapies involving enzalutamide.
- These findings could influence clinical guidelines and treatment protocols for mHSPC globally.
- Long-term follow-up data will provide deeper insights into the durability of response and survival benefits.
